The inhibitory effect of raloxifene on lipopolysaccharide-induced nitric oxide production in RAW264.7 cells is mediated through a ROS/p38 MAPK/CREB pathway to the up-regulation of heme oxygenase-1 independent of estrogen receptor

Biochimie. 2011 Feb;93(2):168-74. doi: 10.1016/j.biochi.2010.09.007. Epub 2010 Oct 1.

Abstract

In this study, we demonstrate that raloxifene, a selective estrogen receptor modulator, is a potent inducer of the anti-inflammatory enzyme heme oxygenase-1 (HO-1). In RAW264.7 macrophages, raloxifene induced HO-1 mRNA and protein expression. Pretreatment of ICI182780, an estrogen receptor (ER) antagonist or knock-down of endogenous ERα or ERβ gene by RNA interference failed to reverse raloxifene-mediated HO-1 induction, indicating an estrogen receptor-independent mechanism. Interestingly, the raloxifene-induced HO-1 expression was suppressed by reactive oxygen species (ROS) scavengers, including glutathione, TEMPO, Me(2)SO, 1,10-phenanthroline, or allopurinol. In addition, buthionine sulfoximine, an inhibitor of reduced glutathione synthesis, or Fe(2+)/Cu(2+) ions enhanced the positive effect of raloxifene on HO-1 expression. Consistent with these findings, raloxifene induced production of intracellular ROS and increased xanthine oxidase activity in vitro. Additional experiments revealed the involvement of mitogen-activated protein kinase (MAPK) kinase6 and p38 MAPK in the up-regulation of HO-1 by raloxifene and identified p38 MAPK as a downstream effector of ROS. Furthermore, the ROS-p38 MAPK cascade targeted the transcription factor cAMP-responsive element-binding protein (CREB). Finally, the functional significance of HO-1 induction was revealed by raloxifene-mediated inhibition of inducible nitric oxide synthase expression and nitric oxide production, a response reversed by the inhibition of HO-1 protein synthesis or blockade of p38 MAPK or xanthine oxidase activity. Therefore, identification of ROS-p38 MAPK-CREB-linked cascade as cellular relays in raloxifene-mediated HO-1 expression defines the signaling events that could participate in raloxifene-mediated anti-inflammatory response.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Anti-Inflammatory Agents / pharmacology
  • Cell Line
  • Cyclic AMP Response Element-Binding Protein / metabolism
  • Enzyme Induction / drug effects
  • Gene Expression Regulation, Enzymologic / drug effects
  • Heme Oxygenase-1 / biosynthesis
  • Heme Oxygenase-1 / metabolism*
  • Hydrogen Peroxide / metabolism
  • Iron / metabolism
  • Lipopolysaccharides / pharmacology*
  • Macrophages / drug effects
  • Macrophages / enzymology
  • Macrophages / metabolism
  • Mice
  • Nitric Oxide / biosynthesis*
  • Nitric Oxide Synthase Type II / metabolism
  • Raloxifene Hydrochloride / pharmacology*
  • Reactive Oxygen Species / metabolism
  • Receptors, Estrogen / metabolism
  • Selective Estrogen Receptor Modulators / pharmacology
  • Signal Transduction / drug effects*
  • Up-Regulation / drug effects*
  • Xanthine / metabolism
  • Xanthine Oxidase / metabolism
  • p38 Mitogen-Activated Protein Kinases / metabolism

Substances

  • Anti-Inflammatory Agents
  • Cyclic AMP Response Element-Binding Protein
  • Fenton's reagent
  • Lipopolysaccharides
  • Reactive Oxygen Species
  • Receptors, Estrogen
  • Selective Estrogen Receptor Modulators
  • Xanthine
  • Nitric Oxide
  • Raloxifene Hydrochloride
  • Hydrogen Peroxide
  • Iron
  • Nitric Oxide Synthase Type II
  • Heme Oxygenase-1
  • Xanthine Oxidase
  • p38 Mitogen-Activated Protein Kinases